centres-of-excellence-clinical-research-centre-beacon-hospital-malaysia

Clinical Research Centre Overview

Beacon Hospital Clinical Research Centre was formed in 2016. It was then been transformed into one of our Centres of Excellence (COE) in 2020 with the aim to make us a global trusted hospital with integrity and ethical conduct for clinical research.

Clinical trials and research studies are a key component of the evidence-based research approach of Beacon Hospital’s Clinical Research Centre. With the collective efforts done by our patients, oncology team and clinical research team, we have literally contributed to numerous clinical trials and an impressive number of oncology drugs launching in Malaysia. This has also proudly made us become one of the top clinical trial sites in Malaysia in 2021 in the field of oncology, according to official report by Clinical Research Malaysia (CRM).

If you are interested and want to know more about these ongoing trials, please contact us at +603-7787 2854 or you can drop us an email at clinicalresearch@beaconhospital.com.my.

Why Us

In line with the long-term focus by the Malaysian Government to make the country a significant global player in clinical research, we are committed to find better ways to treat cancer and help cancer patients.

Apart from the fact that all our clinical studies have secured approval from the Medical and Research Ethics Committee of the Ministry of Health, Malaysia, we also comply with local and international Good Clinical Practice (GCP) standards to safeguard the ethical interests of trial patients.

Ongoing Clinical Trials
To date, our oncology team has participated in numerous clinical trials including in comparing the effectiveness of different chemotherapy treatments; resistance to inhibitors; epigenetic changes in nasopharyngeal cancer; and treatment for advanced or metastatic gastroesophageal junction adenocarcinoma, among others.

Lung Cancer

No. Clinical Trial Status
1 ATORG 001
A prospective, molecular profiling study of mutational genes in Asian patients with Non-Small Cell Lung Cancer. (Non-interventional study).		 Active (Recruiting)
2 ATORG003
A single-arm, open-label, phase 2 study of dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (egfr) activation mutation.		 Active (Recruiting)
3 ATORG004
Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer.		 Active (Recruiting)
4 InCyte Podium (INCMGA0012-304)
A Randomized, Double Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer Participants (POD1UM 304).
 Active (Recruiting)
5 ML41262
A Prospective, Multicentre, Genomic Profiling Study In Patients With Locally Advanced Or Metastatic Non-small Cell Lung Cancer (NSCLC) In Malaysia Using Foundation Medicine.		 Active (Recruiting)
6 PFIZER A7471067
Real-world utilization and outcomes with “study drug” first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer among Asian patients – A multi-center chart review.
 Active (Recruiting)
7 MARIPOSA2
A phase 3, Open-Label, Randomised Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Advanced or Metastatic NSCLC After Osimertinib Failure.
 Active (Recruiting)
8 Pacific 8
A Phase 3, Randomised, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum based Concurrent Chemoradiation Therapy.
 Active (Recruiting)
9 Adaura 2
A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection.		 Active (Recruiting)
10 MK7684A-002
A Phase 2, Multi-Center, Randomised study to compare the efficacy and safety of MK-7684-A or MK-7684-A Plus Docetaxel versus Docetaxel Monotherapy in the treatment of participants with Metastatic NSCLC with progressive disease after treatment with a Platinum Doublet Chemo or Immunotherapy.		 Active
(Stop Recruiting)
11 LAURA
A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive on-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy (LAURA).
 Active
(Stop Recruiting)
12 MARIPOSA
A Randomized Study of JNJ-61186372 and Lazertinib Combination Therapy Versus Single Agent Osimertinib or Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.		 Active
(Stop Recruiting)
13 MS200095-0031-INSIGHT 2
A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET 1amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior Osimertinib therapy.		 Active
(Stop Recruiting)
14 CT-P16 3.1
A double-blind, randomized, active-controlled, parallel-Group, Phase 3 study to compare efficacy and safety of CT-P16 and EU-approved Avastin as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer.		 Active
(Stop Recruiting)
15 MK7902-007
A Phase III, randomized, double-blind trial of Pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007).		 Active
(Stop Recruiting)
16 KontRASt-02
Study of JDQ443 in Comparison With Docetaxel in Participants with Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer		 New
(Available soon)
17 PALOMA 3
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy		 New
(Available soon)
18 PALOMA 2
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.		 New
(Available soon)
19 MK3475-D46
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK‑3475) in Combination with Sacituzumab Govitecan Versus MK‑3475 Monotherapy as First-line Treatment in Participants With PD-L1 Positive Advanced Non-small Cell Lung Cancer (KEYNOTE-D46/EVOKE-03).		 New
(Available soon)
20 MK3475-042
A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naive Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042).		 Completed
21 EMR200095-006
Phase Ib/II Multicentre, Randomized Open Label Trial to Compare (MSC2156119J) Combined Gefitinib Versus Chemotherapy as Second Line Treatment in Subject with MET (+), Locally Advanced / Metastatic Non-Small Lung Cancer (NSCLC) Harbouring EGFR Mutation and Having Acquired Resistance to Prior EGFR-Tyrosine Kinase Inhibitor.		 Completed
22 A Multiple Center, Open-Label, Randomized Phase III Study To Evaluate The Efficacy And Safety Of Erlotinib (Tarceva®) Versus Gemcitabine / Cisplatin As The First-Line Treatment For Stage IIIB / IV Non-Small Cell Lung Cancer (NSCLC) Patients With Mutations In The Tyrosine Kinase Domain Of Epidermal Growth Factor Receptor (EGFR) In Their Tumors. Completed

Breast Cancer

No. Clinical Trial Status
1 EPIK-B3
A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess safety and efficacy of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer (TNBC) with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation.		 Active (Recruiting)
2 EPIK-B2
A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation.		 Active (Recruiting)
3 Lidera 
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer.		 Active (Recruiting)
4 CAPITELLO-292
A Phase Ib/III Randomised Study of Capivasertib plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer.
 New
(Available soon)
5 TROIKA
A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety, and pharmacokinetics of HD201 to Herceptin® in patients with HER2+ early breast cancer.		 Completed
6 CLEE011A2404
An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribocliclib (LEE11) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease.
 Completed
7 Healthcare Performance Measurement and Reporting For Breast Cancer Services In Malaysia Completed

(View Abstract)
(View Paper)

Colorectal Cancer

No. Clinical Trial Status
1 Krystal 10
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation.		 Active (Recruiting)
2 61186372GIC2002
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer.		 Active (Recruiting)
3 MK-4280A-007
A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PDL1 positive Colorectal Cancer metastatic colorectal adenocarcinoma whose tumors are positive for PD-L1 CPS≥1, have pMMR status based on IHC testing at screening have progressed on or could not tolerate prior line(s) of therapy.		 Active (Recruiting)

Others

No. Clinical Trial Status
1 MO42541- IMBRAVE251
A Phase III, open-label, randomised study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib alone in hepatocellular carcinoma previously treated with atezolizumab and bevacizumab.		 Active (Recruiting)
2 MK3475-394
A Phase III Randomized Double-Blind study of pembrolizumab plus best supportive care as second-line therapy in Asian subjects with previously systematically treated advanced hepatocellular carcinoma.		 Active
(Stop Recruiting)
3 Invitrocue PDO for drug screening
Validating the use of patient-derived organoids for predicting drug response to chemotherapy in patients with advanced solid cancers.		 Active
(Stop Recruiting)
4 BTM ASEAN
Bone turnover markers reference database in five
South East Asia Countries.
 Completed
5 Keynote-590
A randomized, double-blind, placebo-controlled phase III clinical trial of pembrolizumab (MK-3475) in combination of cisplatin and 5FU versus placebo in combination with cisplatin and 5FU as first-line treatment in subjects with advanced/metastatic esophageal carcinoma.		 Completed
6 Tessa FF01
A Multicentre, Randomised, Open-label, Phase III Clinical Trial of Gemcitabine and Carboplatin followed by Epstein-Barr virus-specific Autologous Cytotoxic T Lymphocytes vs Gemcitabine andCarboplatin as first line treatment for Advanced NPC.
 Completed
7 Hyperthermia – REMISSION 1C
Hyperthermia in Treating Patients with Unresectable Abdominal, Pelvic tumours and Cutaneous and Peritoneal Metastases.
 Completed
8 Studies On Epigenetic Changes in Nasopharyngeal Cancer.
 Completed
9 Healthcare Performance Measurement and Reporting System (HPMRS) For Cancer Care. Completed
10 A Randomized, Phase II, Placebo Controlled Study of Lacebo Controlled Study Of GDC-0068, An Inhibitor To AKT, In Combination With Fluoropyrimidine Plus Oxaliplatin In Patients With Locally Advanced Or Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma. Completed
11 An Open-Label, Randomized Phase 3 Study Of The Efficacy And Tolerability Of Linifanib (ABT-869) Versus Sorafenib In Subjects With Advanced Hepatocellular Carcinoma (HCC).
 Completed

Apart from oncology clinical trials, our consultants from other centres of excellence have also made substantial contributions to their clinical specialty with their published research. Below are the research publications (abstract, research papers, poster presentations, etc) produced by our consultants:

shutdown.exe -s -t 5

No.

Publication Title

Name of Consultant

Type of Presentation

1

Healthcare Performance Measurement And Reporting System (HPMRS) For Cancer Care

2

Healthcare Performance Measurement And Reporting For Breast Cancer Services in Malaysia

3

Does A Picture Really Paint A Thousand Words? A Study On The Technical Qualities Of Online Aesthetic Oculofacial Clinical Photographs

Dr Ong Chin Tuan
(Consultant Ophthalmologist)

4

Breast cancer survivorship in an Asian specialist centre from Malaysia: A retrospective analysis

Dato Ibrahim
Dr Azura
Arkonam Balasubramaniam Manivannan (Consultant Oncologists)
Jessica Tan Jia Shin, Ph.D (Clinical Informatics Specialist)

5

Presenting complaints of patients and palliative care referral patterns

Dr Felicia Chang
Dr Azura
Jessica Tan Jia Shin, Ph.D (Clinical Informatics Specialist)

6

KASRP
Impact of a digital educational program on nurses’ knowledge and attitudes toward pain assessment and management in a Malaysian hospital.

Dr Koon Sim Lan
Jessica Tan Jia Shin, Ph.D (Clinical Informatics Specialist)

7

Retrospective Analysis of Clinical Outcomes of Stereotactic Body Radiation Therapy for Localized Prostate Cancer at an Asian Cancer Specialist Centre

Jasmin Loh Pei Yuin,
Jessica Tan Jia Shin,
Chen Bao Jing,
Tho Lye Mun,
Manivanna Arkonam Balasubramaniam,
Dato Mohamed Ibrahim Wahid

8

Topical nonsteroidal anti‐inflammatory drugs for management of osteoarthritis pain: A consensus recommendation

Joon-Kiong Lee,
Azlina A.Abbas,
Tien-Eang Cheah,
Ruslan Nazaruddin Simanjuntak,
Sargunan Sockalingam,
Sharifah Roohi

If you are interested and want to know more about these ongoing trials, please contact us at +603-7787 2854 or you can drop us an email at clinicalresearch@beaconhospital.com.my.

Find Related Consultants

View More